Laboral Impact in Patients With Rheumatoid Arthritis (RA) Treated With Advanced Therapies at 12 Months of Treatment

Speaker(s)

Silva Fernández L1, Balsa A2, Sanmartí R3, Rejas J4, Ruiz MA5, Valderrama M6, De Lossada Juste A7, Montoro M6
1Complexo Hospitalario Universitario de A Coruña, Spain, A Coruña, A Coruña, Spain, 2Hospital Universitario La Paz. Universidad Autónoma de Madrid, Madrid, M, Spain, 3Hospital Clinic, Barcelona, Barcelona, Cataluña, Spain, 4EACCOS Research Group, Universidad Autónoma de Madrid, Madrid, Spain, 5School of Psychology, Universidad Autónoma de Madrid, MADRID, Spain, 6Pfizer S.L.U., Alcobendas, Madrid, Spain, 7Pfizer S.L.U., ALCOBENDAS, M, Spain

Presentation Documents

OBJECTIVES: To evaluate RA laboral impact at 12 months of starting an advanced therapy in Spain.

METHODS: This observational, prospective, multicentric study on RA patients who failed to conventional-synthetic-DMARD or first-biologic-DMARD, collected labor information through WPAI questionnaire, and designed interview including laboral patient’s perspective about previous 6 months at baseline visit (M0) and at month 12 visit (M12).

RESULTS: Study includes 118_patients. Labor productivity, (M0 vs M12), according WPAI [mean(SE)] showed [6.46(2.08)-4.75(1.99);p=0.052] absenteeism, [24.46(3.03)-13.27(2.39);p<0.001] presenteeism, [28.58(3.39)-17.56(2.96);p=0.002] productivity and [43.47(2.95)-29.88(2.84);p<0.001] general activity. Labor productivity losses costs [€, year-2022/patient; (SE; CI95%)] were 2,876.00€ (402;2,078-3,673) at M0 and 2,156.00€ (423;1,317;2,995) at M12 (p=0.394). At M12, WPAI showed a difference [mean(SE)] between patients in LDA/remission vs moderate/high activity in presentism [(20.7(3.23) vs 33.33(6.53);p=0.90)], productivity [(24.51(3.73) vs 38.21(7.03);p=0.92)], and general activity [(39.44(3.49) vs 53.00(5.19);p=0.35)].

Regarding to work situation before RA diagnosis 68.3% of patients had full-time job and 16.8% half-time, 1% unemployment, 6.9% housekeepers and 6.9% retired. At M12 visit the rates were 61.4%, 10.9%, 5.9%, 5.0%, and 16.8% respectively.

At M0 22.9% of patients reported that RA has not work impact (RA-WI), 20.3% still in the same job feeling professional development limited, and the rest were fired, o changed job due RA or others. At M12, 76.8% not refer RA-WI and 17,9% still in the same job feeling professional development limited. Patients in RA remission report less RA-WI than patients without remission [Non-RA-WI 93.1%) vs (Non-RA-WI 59.3%) (p=0.013)].

Disability because RA was recognized in 22.7% of patient’s, with no public economic support.

At workplace, at M12, 21.9% of patients did not feel that their RA was understood, 18.8% of patients in LDA/remission and 31.2% of moderate/high activity (p=0.066). RA was unknown at workplace in 12.5%.

CONCLUSIONS: RA has impact on the professional lives of patients. Achieving remission or LDA can improve work productivity.

Code

EE8

Topic

Clinical Outcomes, Economic Evaluation, Study Approaches

Topic Subcategory

Clinical Outcomes Assessment, Novel & Social Elements of Value, Prospective Observational Studies, Work & Home Productivity - Indirect Costs

Disease

Biologics & Biosimilars, Drugs, Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)